Loading...
XSHE000518
Market cap371mUSD
Jan 06, Last price  
2.64CNY
1D
10.00%
1Q
5.60%
Jan 2017
-70.27%
Name

Jiangsu Sihuan Bioengineering Co Ltd

Chart & Performance

D1W1MN
XSHE:000518 chart
P/E
—
P/S
11.55
EPS
—
Div Yield, %
0.03%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
-9.86%
Revenues
235m
-12.86%
311,484,693205,739,418281,083,582281,288,427179,410,436194,079,824208,368,436244,142,021262,466,968208,745,143241,230,724237,843,810327,313,301346,054,646395,514,079417,878,239505,399,427350,961,775270,149,197235,419,049
Net income
-75m
11,222,42607,157,4630023,341,3447,653,669010,066,67505,956,60304,472,9257,288,394014,330,77327,295,10300-75,269,896
CFO
2m
-66.51%
54,051,6450026,919,82168,691,91356,998,249231,621,22320,068,09354,563,537020,089,635011,579,773022,566,81058,632,435100,233,420155,6544,865,7871,629,635
Dividend
Aug 26, 20030.0575 CNY/sh
Earnings
May 21, 2025

Profile

Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.
URL
http://www.000518shsw.com/
IPO date
Sep 08, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
235,419
-12.86%
270,149
-23.03%
Cost of revenue
258,469
272,764
Unusual Expense (Income)
NOPBT
(23,050)
(2,615)
NOPBT Margin
Operating Taxes
989
Tax Rate
NOPAT
(24,040)
(2,615)
Net income
(75,270)
 
Dividends
(766)
(717)
Dividend yield
0.02%
0.02%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
16,017
20,384
Long-term debt
52,946
56,732
Deferred revenue
Other long-term liabilities
3,572
Net debt
49,900
48,396
Cash flow
Cash from operating activities
1,630
4,866
CAPEX
(8,194)
Cash from investing activities
(8,494)
Cash from financing activities
(5,611)
FCF
23,394
45,190
Balance
Cash
19,063
28,341
Long term investments
379
Excess cash
7,292
15,213
Stockholders' equity
1,061,243
1,104,545
Invested Capital
551,550
618,199
ROIC
ROCE
EV
Common stock shares outstanding
1,029,684
1,029,556
Price
3.32
4.73%
3.17
-12.67%
Market cap
3,418,551
4.74%
3,263,693
-12.67%
EV
3,499,524
3,348,343
EBITDA
1,552
22,137
EV/EBITDA
2,254.26
151.25
Interest
2,506
717
Interest/NOPBT